

Drug	FORMULATION	INDICATION	TRIALS	COMPANY	BRAND NAME	APPROVAL DATE
EXENATIDE	Once-weekly injectable	T2D	DURATION	AstraZeneca	Byetta/Bydureon	2005
LIRAGLUTIDE	Once-daily injectable	T2D	LEAD	Novo Nordisk	Victoza	2010
DULAGLUTIDE	Once-weekly injectable	T2D	AWARD	Eli Lilly	Trulicity	2014
LIRAGLUTIDE	Once-daily injectable	obesity/weight management	SCALE	Novo Nordisk	Saxenda	2014
LIXISENATIDE	Once-daily injectable	T2D	GetGo	Sanofi	Lyxumia/Adlyxin	2016
SEMAGLUTIDE	Once-weekly injectable	T2D	SUSTAIN	Novo Nordisk	Ozempic	2017
SEMAGLUTIDE	Once-weekly injectable	obesity/weight management	STEP	Novo Nordisk	Wegovy	2021
SEMAGLUTIDE	Once-daily oral	T2D	PIONEER	Novo Nordisk	Rybelsus	2023

CLASS	MECHANISM	COMPANY	CLINICAL PHASE	NCT
"INCRETINS PLUS"	Bispecific GIPR antagonist/GLP-1 R agonist	Amgen	Phase 1 (Complete) Phase 2 (Recruiting)	NCT04478708 NCT05669599
	GIP/GLP/glucagon triple agonist	Eli Lilly	Phase 2 Phase 3 (recruiting)	NCT04143802
	GIP/GLP/glucagon triple agonist	Hanmi Pharma	Phase 1b/2a	NCT04505436
	Dual GLP-1R and glucagon agonist	NeuroBo Pharma	Phase 1 (Complete T2D)	
HORMONAL MODULATORS	Leptin sensitizer	ERX Pharmaceuticals	Phase 1	NCT04890873
	PYY analog + semaglutide	Novo Nordisk	Phase 1 (Complete)	NCT03707990 NCT04969939
	Amylin analog	Novo Nordisk	Phase 2	NCT04940078
	Amylin/Calcitonin dual agonist	Nordic Biosciences	Phase 1 (T2D)	NCT03907202
NOVEL MECHANISM	GDf15 analog	Eli Lilly	Phase 2	NCT03764774
	Mitochondrial uncoupler	Rivus	Phase 2b	NCT04874233
	Activin type II receptor blockade	Versanis	Phase 2b	NCT05616013
	Gut-brain axis modulator	Kallyope	Phase 1	
CELL THERAPY	miR-22 inhibitor	Resalis	Preclinical	NA
	Bioprinted tissue therapeutics - pancreatic	Novo Nordisk + Aspect Biosystems	Preclinical	NA